Outcome | Complications | Total cost (£ per patient)* | Number of patients | Probability | Average QALY±SD | Assigned QALY for sensitivity analysis 1 | Assigned QALY for sensitivity analyses 2 and 3 |
PAE | |||||||
1 | HU, HS, UI | 2010.04 | 1 | 0.008 | 1.00±0.00 | 0.93 | 0.89 |
2 | HU, HS, RE | 2000.00 | 4 | 0.030 | 0.97±0.02 | 0.96 | 0.89 |
3 | HU, HS | 2000.00 | 6 | 0.045 | 0.95±0.03 | 0.96 | 0.89 |
4 | HU, RE | 2000.00 | 3 | 0.023 | 0.97±0.03 | 0.96 | 0.89 |
5 | HU | 2000.00 | 16 | 0.120 | 0.97±0.03 | 0.96 | 0.89 |
6 | HS, RE | 2000.00 | 0.008 | 0.97±0.00 | 0.96 | 0.89 | |
7 | HS | 2000.00 | 5 | 0.038 | 0.97±0.03 | 0.96 | 0.89 |
8 | I | 3203.33 | 0.008 | 0.97±0.00 | 0.89 | 0.89 | |
9 | UI | 2010.04 | 5 | 0.038 | 0.93±0.05 | 0.93 | 0.89 |
10 | RE | 2000.00 | 6 | 0.045 | 0.97±0.05 | 0.96 | 0.89 |
11 | Nil | 2000.00 | 85 | 0.639 | 0.96±0.03 | 0.96 | 0.96 |
Total | – | – | 133 | 1.000 | 0.96±0.03 | – | – |
TURP | |||||||
1 | HU, HS | 3028.00 | 1 | 0.032 | 1.00±0.00 | 0.99 | 0.89 |
2 | HU, I, RE | 4231.33 | 1 | 0.032 | 0.94±0.00 | 0.89 | 0.89 |
3 | HU, UI, RE | 3038.04 | 1 | 0.032 | 1.00±0.00 | 0.93 | 0.89 |
4 | HU, RE | 3028.00 | 11 | 0.355 | 0.98±0.03 | 0.99 | 0.89 |
5 | HU | 3028.00 | 7 | 0.226 | 0.97±0.04 | 0.99 | 0.89 |
6 | RE | 3028.00 | 5 | 0.161 | 0.98±0.02 | 0.99 | 0.89 |
7 | Nil | 3028.00 | 5 | 0.161 | 0.99±0.02 | 0.99 | 0.99 |
Total | – | 31 | 1.000 | 0.98±0.03 | – | – |
*Total cost (in £ per patient) for each outcome was derived by adding the intervention cost (see table 1) to the cost of managing the observed complications (see online supplemental table S3).
HS, hematospermia; HU, hematuria; I, incontinence; PAE, prostate artery embolization; QALY, quality-adjusted life year; RE, retrograde ejaculation; TURP, transurethral resection of the prostate; UI, urinary infection.